Free Trial
NASDAQ:ANNX

Annexon Q4 2024 Earnings Report

Annexon logo
$1.97 +0.12 (+6.20%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.97 0.00 (0.00%)
As of 05/2/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annexon EPS Results

Actual EPS
-$0.33
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Annexon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Annexon Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 3, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Annexon's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Thursday, May 15, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Annexon Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Annexon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annexon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annexon and other key companies, straight to your email.

About Annexon

Annexon (NASDAQ:ANNX), a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

View Annexon Profile

More Earnings Resources from MarketBeat